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Glucagon secretion is inhibited by glucagon-like
peptide-1 (GLP-1) and stimulated by adrenaline.
These opposing effects on glucagon secretion are
mimicked by low (1–10 nM) and high (10 mM) concen-
trations of forskolin, respectively. The expression of
GLP-1 receptors in a cells is <0.2% of that in b cells.
The GLP-1-induced suppression of glucagon secre-
tion is PKA dependent, is glucose independent, and
does not involve paracrine effects mediated by
insulin or somatostatin. GLP-1 is without much effect
on a cell electrical activity but selectively inhibits
N-type Ca2+ channels and exocytosis. Adrenaline
stimulates a cell electrical activity, increases [Ca2+]i,
enhances L-type Ca2+ channel activity, and acceler-
ates exocytosis. The stimulatory effect is partially
PKA independent and reduced in Epac2-deficient
islets. We propose that GLP-1 inhibits glucagon
secretion by PKA-dependent inhibition of the N-type
Ca2+ channels via a small increase in intracellular
cAMP ([cAMP]i). Adrenaline stimulates L-type Ca
2+
channel-dependent exocytosis by activation of the
low-affinity cAMP sensor Epac2 via a large increase
in [cAMP]i.INTRODUCTION
Glucagon is the most important hyperglycaemic hormone of
the body (Cryer, 2002). In both type 1 and type 2 diabetes, hyper-
glycaemia results from a combination of insufficient insulin
secretion and oversecretion of glucagon (Dunning et al., 2005;
Unger, 1985). In addition, glucagon secretion in diabetic patients
also exhibits impaired counterregulation and does not increaseCappropriately when blood glucose falls to dangerously low levels
(Cryer, 2002).
Glucagon is secreted from a cells in pancreatic islets. Secre-
tion of glucagon is influenced by both intrinsic and paracrine
control (exerted by factors released from neighboring b and
d cells) (Gromada et al., 2007; Macdonald et al., 2007). Glucagon
secretion is also under tight neuronal and hormonal control (Miki
et al., 2001). Examples of agonists regulating glucagon release
include GLP-1, glucose-dependent insulinotropic peptide
(GIP), and adrenaline. These hormones all act via stimulation of
cAMP production (Ma et al., 2005; Olsen et al., 2005). GLP-1
inhibits glucagon secretion, whereas GIP and adrenaline stimu-
late its release (de Heer et al., 2008; Pipeleers et al., 1985).
How can compounds that share the same intracellular second
messenger have opposite effects on secretion? The answer to
this conundrum may provide valuable insights into the regulation
of a cell exocytosis.
Here we have compared the effects of GLP-1, adrenaline, GIP,
and forskolin (all of which activate adenylate cyclase and stimu-
late cAMP production) on glucagon secretion and cAMP
content. Our data suggest that the opposite effects of GLP-1
and adrenaline correlate with their different receptor densities
and correspondingly different capacities to increase intracellular
cAMP. This culminates in selective activation of two different
cAMP-binding proteins with different affinities for cAMP, PKA,
and Epac2. We propose that variable activation of these two
cAMP sensors mediates the opposite effects on glucagon
secretion.RESULTS
Comparison of the Effects of GLP-1, GIP, andAdrenaline
on Glucagon Secretion
Figure 1A compares the effects of GLP-1, GIP, and adrenaline
on glucagon secretion from mouse islets. GIP and adrenaline
stimulated glucagon secretion 130% and 350%, respectively,
whereas GLP-1 inhibited glucagon secretion by 50%. The latterell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc. 543
Figure 1. Divergent Effects of cAMP-Increasing Agents onGlucagon
Secretion and Involvement of PKA
(A) Glucagon secretion measured from isolated mouse islets in 0 mM glucose
(Ctrl) and in the presence of 100 nM GLP-1, 100 nM GIP, or 5 mM adrenaline
(Adr). ***p < 0.001 versus ctrl.
(B) As in (A), but in the presence of 10 mM of the PKA inhibitor 8-Br-Rp-cAMPS
as indicated. yyp < 0.01 versus Ctrl; zp < 0.05, zzzp < 0.001 for comparison with
corresponding values in (A). Data have been normalized to control (10.4 ±
0.5 pg/islet/hr; n = 8–16).
(C) Glucagon secretion measured in the absence (>) and presence (-) of
100 nM GLP-1 at different glucose concentrations (1–20 mM). **p < 0.01 and
***p < 0.001 for effect of GLP-1 compared at the respective glucose concen-
trations. Data have been normalized to control (1 mM glucose; 30.4 ±
1.5 pg/islet/hr; n = 8).
(D) Glucagon secretion measured at 3 mM glucose in the absence and pres-
ence of 100 nM GLP-1 with or without addition of adrenaline (Adr, 5 mM).
Data have been normalized to value at 1 mM (in C; 30.4 ± 1.5 pg/islet/hr;
n = 8). *p < 0.05, ***p < 0.001 versus control and yyyp < 0.001 versus GLP-1.
(E) Effects of 10 nM GLP-1 in the absence and presence of 100 nM of the
SSTR2 antagonist CYN154806 as indicated. Glucose was present at 1 mM.
Data have been normalized to control (2.1 ± 0.1 pg/islet/hr, n = 7). **p < 0.01
and ***p < 0.001 versus control and yyp < 0.01 versus CYN154806 alone.
(F) Expression of GLP-1 (Glp1r), GIP (Gipr), and b1- and b2-adrenergic recep-
tors (Adrb1 and Adrb2) in mouse b cells.
(G) Same as in (F) but using mouse a cells. Data have been normalized to Glp1r
expression in mouse b cells. Note use of different ordinate scales in (F) and (G).
(H) Fraction GLP-1R-positive cells of insulin (b cells) and glucagon positive
(a cells).
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statin secretion (see Figures S1A and S1B available online).
The PKA inhibitor 8-Br-Rp-cAMPS did not affect glucagon
secretion observed in the absence of glucose but reduced the
inhibitory and stimulatory effects of GLP-1 (to 15% reduction),
GIP (to <20% stimulation), and adrenaline (to 150% enhance-
ment). Thus, 40% of the stimulatory action of adrenaline
in this series of experiments was resistant to PKA inhibition
(Figure 1B).
The inhibitory effect of GLP-1 occurred over a wide range of
glucose concentrations (1–20 mM, Figure 1C) and was counter-
acted by adrenaline (Figure 1D). GLP-1 remained inhibitory in the
presence of the somatostatin receptor subtype-2 (SSTR2)
antagonist CYN154806. In the presence of CYN154806, glu-
cagon secretion at 1 mM glucose alone was stimulated 2-fold,
but GLP-1 still inhibited glucagon release by 40% (Figure 1E).
GIP, GLP-1, and b-Adrenoreceptor Densities
in Mouse a and b Cells
Pure a and b cell fractions were obtained by FACS of dispersed
islets from mice expressing YFP under the proglucagon
promoter (Reimann et al., 2008). Mouse b cells expressed the
GLP-1 receptor gene (Glp1r) at high levels. The GIP receptor
was also expressed at fairly high levels in b cells (25% of
Glp1r), whereas the mRNAs for b1 and b2 adrenoreceptors
(Adrb1 and Adrb2) were only present at low levels (Figure 1F).
In mouse a cells, Glp1r was expressed at 0.17% of that found
in b cells, whereas Gipr and Adrb1 and Adrb2 were expressed
at 25- to 40-fold higher levels (Figure 1G). The a cell fraction
consists almost exclusively of a cells (99.98% based on the total
amount of insulin, glucagon, and somatostatin mRNA). Thus, the
expression of Glp1r in a cells is >8-fold higher than can be
accounted for by contamination of the a cell fraction by b cells.
The PCR data were confirmed by immunocytochemistry.
Eighty per cent of the insulin-positive b cells costained with an
anti-GLP-1R antibody, whereas only1% of the glucagon-posi-
tive a cells contained detectable GLP-1R immunoreactivity (Fig-
ure 1H and Figure S1C).
The inhibitory effect of GLP-1 was abolished in the presence of
the GLP-1R antagonist exendin (9-39) (Figure 1I).
Increasing Concentrations of Forskolin and Adrenaline
Exert Dual Effects on Glucagon Secretion
Low concentrations of forskolin (1–10 nM) mimicked the effect of
GLP-1 and inhibited glucagon secretion by up to 60%, whereas
high concentrations (0.1–10 mM) produced an adrenaline-like
concentration-dependent stimulation (Figure 2A). The inhibi-
tion produced by 1–10 nM forskolin is not due to stimulation of
somatostatin secretion (Figure S2) or insulin secretion (data not
shown, but see McQuaid et al., 2006).
Inhibition of PKA by 8-Br-Rp-cAMPS did not affect glucagon
release evoked by 1 mM glucose alone (Figure 2B). However,
the inhibitory action of 3 nM forskolin was abolished. The stimu-
lation evoked by 10 mM forskolin was completely resistant to(I) Glucagon secretion at 1 mM glucose (Ctrl) and in the presence of 1 mM of
exendin (9-39) (Ex 9-39) and/or 100 nM GLP-1 as indicated. Data have been
normalized to control (9.3 ± 0.3 pg/islet/hr; n = 11–12). ***p < 0.001 versus
control; yyyp < 0.001 versus GLP-1 alone.
Figure 2. Concentration-Dependent Effects of Forskolin and Adren-
aline on Glucagon Secretion and cAMP Production
(A) Effects of increasing concentrations of forskolin (0–10 mM) on glucagon
secretion at 0 mM glucose. Data have been normalized to control (13.0 ±
0.9 pg/islet/hr; n = 8). ***p < 0.001 versus rate of secretion in the absence of
forskolin.
(B) Glucagon secretion at 1 mM glucose (Ctrl) with or without addition of 3 or
10 mM forskolin (FSK) in the absence (left) and presence (right) of 10 mM
8-Br-Rp-cAMPS. Data have been normalized to control (7.1 ± 0.3 pg/islet/hr;
n = 6–12).*p < 0.05 and ***p < 0.001 versus Ctrl; yyp < 0.01 and zzzp < 0.001
versus Ctrl in the presence of 8-Br-Rp-cAMPS.
(C) Glucagon secretion with increasing concentrations of cAMP. Glucagon and
cAMP content were measured in islets exposed to increasing concentrations
of forskolin (0–10 mM; concentrations (in mM) are given next to the data points)
in the presence of 1 mM glucose. Data have been normalized to control (2.8 ±
0.5 pg/islet/hr; n = 8). ***p < 0.001 and **p < 0.01 versus secretion in the
absence of forskolin.
(D) Effects of increasing concentrations of adrenaline (50 pM–5 mM) on glucagon
secretion. Gray rectangles indicate glucagon secretion at 1 mM glucose alone
(top) and 8 mM glucose (bottom). Experiments were performed in the presence
of 1 mM glucose. Data have been normalized to control (4.9 ± 0.34 pg/islet/hr;
n = 4). ***p < 0.001 and *p < 0.05 versus secretion in the absence of adrenaline.
(E) Confocal immunostaining of cells dispersed from single mouse islets. Cells
were labeled with antibodies against glucagon (red) and PKA-RI (green). Right-
most panel shows the superimposed images (merge).
(F) As in (E) but using antibody against PKA-RII.
(G) Schematic illustration of image analysis. The ratio between near-plasma
membrane and cytosolic immunoreactivity was determined using the equation
inserted into the image.
(H) Ratio between near-plasma membrane and cytosolic immunoreactivity
calculated as illustrated in (G). ***p < 0.001 (n = 10 for PKA-RI and PKA-RII).
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CPKA inhibition (conceivably because high cAMP levels antago-
nize the inhibitory action of 8-Br-Rp-cAMPS).
Measurements of cAMP in intact islets indicate that intra-islet
cAMP concentration increases from 2 fmol/islet under control
conditions to 10 fmol/islet in 10 nM forskolin and 50–
100 fmol/islet in 1–10 mM forskolin (Figure 2C). Parallel measure-
ments of glucagon release revealed that inhibition was maximal
when the islet cAMP content was 10 fmol/islet and that stimu-
lation occurred at concentrations above 50 fmol/islet.
We also determined the relationship between the adrenaline
concentration and glucagon secretion. A high concentration of
adrenaline (5 mM) stimulated glucagon secretion, whereas lower
concentrations (50 pM–500 nM) were inhibitory (Figure 2D).
Two different PKA isozymes have been identified: PKA type I
and type II (PKAI and PKAII). PKAI is more sensitive to cAMP
than PKAII because its regulatory subunit (PKA-RI) has a higher
cAMP affinity than the regulatory subunit of PKAII (PKA-RII)
(Cummings et al., 1996). We applied confocal microscopy to
visualize the distribution of PKA-RI and PKA-RII. Both subunits
were detected in a cells (Figures 2E and 2F). PKA-RII was
present throughout the cells, whereas PKA-RI showed preferen-
tial near-plasma membrane localization (Figures 2G and 2H).
Membrane Potential-Dependent Effects of GLP-1,
Adrenaline, and Forskolin
Glucagon secretion shows a biphasic dependence on the extra-
cellular K+ concentration ([K+]o; Gromada et al., 2004). Figure 3A
shows the changes in membrane potential recorded from a cells
in intact islets when the [K+]o was increased from 3.6 mM to
15 mM, 30 mM, and 70 mM. Unlike b and d cells, a cells are elec-
trically active at low (1 mM) glucose, and many of the cells gener-
ated overshooting action potentials. Application of the highest
[K+]o resulted in a sustained depolarization, whereas the two
lower [K+]o resulted in weaker depolarization and reduced action
potential amplitude. At 3.6 mM [K+]o, the action potentials
peaked at 2 ± 7 mV, which was reduced to –16 ± 6 mV at
15 mM [K+]o (n = 4; p < 0.05).
Figure 3B compares the effects of varying [K+]o on a cell
membrane potential and glucagon secretion. The relationship
between [K+]o and membrane potential suggests a 33 ± 3 mV
change for a 10-fold variation of [K+]o (Figure S3). This is less
than the 60 mV expected if the membrane potential was solely
determined by the K+ permeability. Increasing [K+]o from the
normal 4.7 mM to 10–15 mM inhibits glucagon secretion by
50%, and concentrations >30 mM K+ are required to stimulate
glucagon secretion.
In the presence of 10 mM forskolin, no inhibition of glucagon
secretion was produced by intermediate [K+]o (Figure 3B). For-
skolin stimulated glucagon secretion 1.4- to 5.3-fold; the stron-
gest stimulation was observed at an [K+]o of 15 mM. Like forsko-
lin, adrenaline stimulated glucagon secretion at 4.7, 15, and
65 mM [K+]o (Figure 3C). Increasing [K
+]o to 15 mM inhibited
glucagon secretion to the same extent as that produced by
GLP-1. At this intermediate [K+]o, GLP-1 exerted no additional
inhibitory effect (Figure 3C).
These observations suggest that in the presence of forskolin or
adrenaline, glucagon secretion can proceed at more negative
membrane potentials than under control conditions. Perforated
patch whole-cell capacitance measurements were used toell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc. 545
Figure 3. Cyclic AMP-Dependent Modulation of the Membrane
Potential Dependence of Glucagon Secretion
(A) Membrane potential recordings from a cells within intact islets (spontane-
ously active at 1 mM glucose) at 3.6, 15, 30, and 70 mM extracellular K+ (as
indicated).
(B) Glucagon secretion measured at extracellular K+ concentrations ([K+]o)
between 2.5 and 65 mM under control conditions (,) and in the presence of
10 mM forskolin (d). Glucose was present at 1 mM. The membrane potentials
indicated (top) were obtained from experiments of the type as shown in (A)
(n = 7, 4, 4, 3, at 3.6, 15, 30, and 70 mM). Secretion data have been normalized
to control (34.4 ± 4.5 pg/islet/hr measured at 4.7 mM [K+]o; n = 4–8). All values
in the presence of forskolin are significantly different from corresponding
control values (p < 0.01 or better). Glucagon release under control conditions
at 15 mM [K+]o is significantly (p < 0.05) lower, while glucagon secretion at 32
and 65 mM [K+]o is significantly (p < 0.001) higher than that at 4.7 mM [K
+]o.
(C) Glucagon secretion measured at 4.7, 15, and 65 mM [K+]o (control, y¨) and in
the presence of 5 mM adrenaline (d) or 100 nM GLP-1 (:). Glucose was present
at 1 mM. Data have been normalized to glucagon secretion at 4.7 mM [K+]o
(33.4 ± 1.5 pg/islet/hr; n = 10). ***p < 0.001 for adrenaline versus control and
yyyp < 0.001 for GLP-1 versus control.
(D) Changes in membrane capacitance (DCm) displayed against membrane
potential of depolarization (V) under control conditions (y¨) and 4 min after appli-
cation of 10 mM forskolin (d). n = 5 cells. *p < 0.05; **p < 0.01 versus control.
The inset shows the response to a depolarization to –20 mV.
(E) As in (D) but comparing responses in the presence of 5 mM adrenaline (d)
with control responses (,). n = 5 cells. *p < 0.05; **p < 0.01; ***p < 0.001 versus
control.
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Under control conditions, depolarization-evoked exocytosis
was small, the maximum response was observed during a depo-
larization to 0 mV, where it averaged 50 fF. Much larger
responses were obtained in the presence of 10 mM forskolin (Fig-
ure 3D); the maximum response was observed during a depolar-
ization to –10 mV, where it averaged 250 fF. Importantly,
exocytosis proceeded at membrane potentials in the presence
of forskolin that were not associated with much exocytosis under
control conditions. Thus, forskolin enhanced exocytosis elicited
by a depolarization to 20 mV >10-fold; from 6 ± 4 fF (n = 5)
under control conditions to 64 ± 12 fF (p < 0.01) after the addition
of forskolin. Adrenaline (5 mM) had similar, albeit less pro-
nounced effects (Figure 3E); exocytosis elicited by a depolariza-
tion to 20 mV increased from 1 ± 2 fF (n = 5) under control
conditions to 13 ± 3 fF (p < 0.01) in the presence of adrenaline.
Involvement of Epac2 in the Stimulation of Exocytosis
The effects of forskolin and adrenaline on a cell exocytosis were
mimicked by intracellular application of 100 mM 8CPT-2Me-
cAMP, a selective agonist of the low-affinity cAMP sensor
Epac2 (Enserink et al., 2002). The maximum response was
increased 10-fold and depolarizations to voltages as negative
as 20 mV evoked significant exocytotic responses (Figures
4A and 4B). Under control conditions, a depolarization to –20 mV
produced a capacitance increase of 2 ± 1 fF (n = 7), which
increased to 19 ± 3 fF (p < 0.001, n = 13) in the presence of
8CPT-2Me-cAMP. Isradipine (2 mM) inhibited the stimulation of
exocytosis by 8CPT-2Me-cAMP by 60%, whereas exocytosis
elicited by normal cAMP was inhibited by 90% (Figure S4). The
8-CPT-2Me-cAMP-induced stimulation of exocytosis was asso-
ciated with a doubling of the whole-cell Ca2+ current, an effect
antagonized by isradipine (Figures 4C and 4D).
We further examined the role of Epac2 in the control of
glucagon release by using islets from Epac2 knockout mice
(Figures 4E and 4F) (Shibasaki et al., 2007). Consistent with the
results of Figure 1, glucagon secretion in wild-type mouse islets
was stimulated 5-fold by adrenaline and inhibited >60% in
response to GLP-1 (Figure 4E). In Epac2 knockout islets, GLP-1
remained inhibitory, but the effect of adrenaline was limited to
a2-fold stimulation of glucagon release. Thus, 80% of the stim-
ulatory effect of adrenaline is Epac2 dependent. In both wild-
type and Epac2-deficient islets the inhibitory effect of GLP-1
on glucagon secretion was strongly reduced by 8-Br-Rp-cAMPs
(but the stimulatory effect of adrenaline in the wild-type was still
statistically significant; p < 0.001). Notably, the PKA-indepen-
dent (8-Br-Rp-cAMPS-resistant) stimulation of glucagon secre-
tion evoked by adrenaline was abolished in Epac2-deficient
islets (Figure 4F).
Effects of GLP-1 and Adrenaline on [Ca2+]i in a Cells
in Intact Mouse Islets
Many cells in intact islets exposed to 1 mM glucose exhibited
spontaneous [Ca2+]i oscillations (Figure 5A). In a series con-
ducted on 18 islets from five mice, 87 ± 4 fluorescent cells
were identified in the islet cross-section (18,700 ± 1,200 mm2)
cells. Of these, 24 ± 2 cells (28%) were active at 1 mM glucose.
Adrenaline elicited a strong response in 71% of the cells that
were spontaneously active at 1 mM glucose (n = 28 cells from
Figure 4. Involvement of Epac2 in a Cell Exocytosis and Glucagon
Secretion
(A) Changes in membrane capacitance (DCm) elicited by voltage-clamp depo-
larization from 70 to 10 mV under control conditions (Ctrl), in the presence
of 0.1 mM of the Epac2 agonist 8CPT-2Me-cAMP (8-CPT) and in the simulta-
neous presence of 8CPT-2Me-cAMP and 2 mM isradipine (Isr + 8-CPT).
(B) Changes in membrane capacitance (DCm) displayed against membrane
potential of depolarization (V) under control conditions (-), after inclusion
of 0.1 mM 8CPT-2Me-cAMP in the intracellular medium (O), and in 8CPT-
2Me-cAMP containing cells exposed to 2 mM isradipine (:). Data are mean
values ± SEM of 7–13 experiments. *p < 0.05, **p < 0.01, and ***p < 0.001
for comparisons between 8CPT-2Me-cAMP alone or 8CPT-2Me-cAMP in
the simultaneous presence of isradipine versus control. yyp < 0.01 for values
in simultaneous presence of 8CPT-2Me-cAMP and isradipine versus 8CPT-
2Me-cAMP alone.
(C) Whole-cell Ca2+ currents recorded under control conditions (Ctrl), after
intracellular application of 100 mM 8-CPT-2Me-cAMP (8-CPT) and in the pres-
ence of 8-CPT and 2 mM isradipine.
(D) Peak Ca2+ currents recorded under control conditions (-), after intracel-
lular addition of 8-CPT (B) and after intracellular application of 8-CPT
when L-type Ca2+ channels were blocked by isradipine (2 mM). *p < 0.05 and
**p < 0.01 for the stimulatory effects of 8-CPT (versus Ctrl) and yp < 0.05 and
yyp < 0.01 for the effect of isradipine (versus 8-CPT). (n = 5–10 experiments
in each group).
(E) Glucagon secretion from wild-type mouse islets under control conditions
(Ctrl; 1 mM glucose), in the presence of 100 nM GLP-1 or 5 mM adrenaline
(Adr) in the absence and presence of 10 mM 8-Br-Rp-cAMPS. n = 6–8.
**p < 0.01 and ***p < 0.001 versus Ctrl in the absence or presence of 8-Br-
Rp-cAMPS; yyp < 0.01 and yyyp < 0.001 versus corresponding value in the
absence of 8-Br-Rp-cAMPS. Glucose was present at 1 mM.
(F) As in (C) using islets from Epac2 null mice. n = 5–8. **p < 0.01 and
***p < 0.001 versus Ctrl in the absence or presence of 8-Br-Rp-cAMPS.
yyp < 0.05 versus corresponding value in the absence of 8-Br-Rp-cAMPS.
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of a large [Ca2+]i increase or a series of high-frequency oscilla-
tions. This suggests that the majority of cells active in 1 mM
glucose are a cells (Berts et al., 1996; Quoix et al., 2007). In 12
representative cells that responded to adrenaline, GLP-1 wasCwithout consistent effect and did not change the area under
the curve divided by time (AUC/t). By contrast, adrenaline
increased AUC/t to 220% ± 51% of control (p < 0.05).
Mouse a cells are equipped with N- and L-type Ca2+ channels
(Macdonald et al., 2007). We compared the effects of the L- and
N-type Ca2+ channel blockers isradipine and u-conotoxin on
[Ca2+]i. In islets exposed to 1 mM glucose, u-conotoxin reduced
the [Ca2+]i oscillation peak amplitudes by 39% ± 11% (p < 0.02;
Figure 5B). Subsequent addition of isradipine reduced the
average peak height by a further 85% ± 5% (p < 107). When
isradipine was used without the prior addition of u-conotoxin,
oscillation amplitudes were reduced by only 35% ± 14% (p <
0.001; Figure S5A). Subsequent addition ofu-conotoxin lowered
the amplitude by an additional 36% ± 7% (p < 0.05 versus isra-
dipine alone). Addition of adrenaline in the combined presence of
isradipine and u-conotoxin evoked a transient elevation of
[Ca2+]i, possibly reflecting the a1-adrenoceptor-evoked
response previously described in isolated mouse a cells (Vieira
et al., 2004).Cyclic AMP Causes a Switch in the Ca2+ Channel
Dependence of Exocytosis in a Cells from N to L Type
Glucagon secretion elicited by low glucose alone was inhibited
by the N-type Ca2+ channel blocker u-conotoxin but unaffected
by the L-type Ca2+ channel blocker nifedipine. In the presence of
10 mM forskolin, however, u-conotoxin was almost without
effect, whereas the forskolin-induced stimulation was abolished
by nifedipine (Figure 5C).
We examined the ability of the Ca2+ channel antagonists to
block the effects of GLP-1, GIP, and adrenaline on glucagon
secretion (Figures 5D and 5E). Glucagon secretion at 1 mM glu-
cose was again strongly inhibited by u-conotoxin, and GLP-1
exerted no further inhibitory effect in the presence of this blocker.
GIP and adrenaline stimulated glucagon release 1.6- and 3-fold
under control conditions, and they remained stimulatory in the
presence of u-conotoxin. Isradipine did not affect glucagon
secretion at 1 mM glucose alone and the inhibitory effect of
GLP-1 but abolished the stimulation evoked by both GIP and
adrenaline (Figure 5E).Effects of GLP-1, u-Conotoxin, Adrenaline,
and Somatostatin on a Cell Electrical Activity
We recorded electrical activity from a cells in intact mouse islets
(Figure 6). The effects of GLP-1 on a cell electrical activity were
tested in a total of six islets with no obvious and consistent
effects. In three of the experiments, electrical activity was
consistent enough to allow quantitative analysis. Addition of
GLP-1 transiently (2–3 min) hyperpolarized the a cell (the inter-
spike membrane potential decreased from 51 ± 1 mV to
–57 ± 1 mV; n = 3; p < 0.05). This hyperpolarization was associ-
ated with increased action potential amplitude in two of the three
cells tested. The a cells subsequently depolarized in continued
presence of GLP-1 to –49 ± 1 mV, and the peak voltage of the
action potentials averaged –1 ± 4 mV (not significantly different
from the 0.5 ± 3 mV observed before addition of GLP-1).
GLP-1 did not affect the frequency of the action potentials which
averaged 4 ± 2 Hz under control conditions and 3 ± 1 Hz in the
presence of GLP-1 (at steady state).ell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc. 547
Figure 5. Effects of GLP-1, Adrenaline, and
Ca2+ Channel Blockers on a Cell [Ca2+]i
and Glucagon Secretion
(A) Spontaneous [Ca2+]I oscillations in individual
a cells in intact mouse islets exposed to 1 mM
glucose and effects of including 10 nM GLP-1 or
5 mM adrenaline in the perfusion medium during
the periods indicated by horizontal lines. n = 12
cells in four islets from three mice.
(B) As in (A), but 100 nM u-conotoxin and 2 mM
isradipine were applied. n = 14 cells in four islets
from two mice.
(C) Glucagon secretion at 1 mM glucose (Ctrl) and
in the presence of 10 mM forskolin in the absence
(left) and presence of 1 mM u-conotoxin (middle)
or 50 mM nifedipine (right). Data have been normal-
ized to control in the absence of forskolin and
the Ca2+ channel blockers (30.7 ± 1.2 pg/islet/h;
n = 8–10). ***p < 0.001 versus respective control
(Ctrl) in the absence or presence of u-conotoxin
or isradipine. yyyp < 0.001 versus corresponding
value in the absence of u-conotoxin or isradipine.
(D) As in (C) but comparing the effects of 100 nM
GLP-1, 100 nM GIP, and 5 mM adrenaline (Adr) in the absence (left) and presence (right) of 100 nM u-conotoxin. n = 10. *p < 0.05, **p < 0.01, and
***p < 0.001 versus respective Ctrl in the absence or presence of u-conotoxin; yyp < 0.01 versus corresponding value in the absence of u-conotoxin.
(E) As in (D), but 2 mM isradipine was applied. n = 7–10. *p < 0.05 and ***p < 0.001 versus Ctrl; yp < 0.001 versus GIP in absence of isradipine and yyyp < 0.001 versus
adrenaline in absence of isradipine.
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(Figure 6C). The N-type Ca2+ channel blocker neither affected
the interspike voltage (48 ± 2 mV before and after addition of
u-conotoxin, n = 5) nor frequency (5 ± 2 Hz under both condi-
tions) but reduced the peak of the action potentials from –6 ±
5 mV to –9 ± 4 mV (p < 0.05, paired t test).
Adrenaline had more dramatic effects on a cell membrane
potential than GLP-1 (Figure 6E). Application of adrenaline
reversibly depolarized the a cell from –49 ± 2 mV to –40 ±
2 mV (n = 5; p < 0.01). This was associated with a decrease in
the action potential peak voltage from –8 ± 2 mV to –20 ± 1 mV548 Cell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc.(p < 0.05). The action potential frequency was not affected (4 ±
1 Hz under control conditions and 4 ± 2 Hz in the presence of
adrenaline), but their duration increased 5-fold. Thus, the
percentage of the time the membrane potential was above
20 mV increased from 2.1% ± 0.8% under control conditions
to 10% ± 3.1% in the presence of adrenaline (p < 0.05).
Somatostatin transiently abolished action potential firing
(in two of two cells tested) and hyperpolarized the a cells by
17 and 15 mV. Action potential firing then spontaneously resumed
in the continued presence of somatostatin, but their frequency
was reduced by 50% and their amplitude increased by 10 andFigure 6. Effects of GLP-1, u-Conotoxin,
Adrenaline, and Somatostatin on Mouse
a Cell Electrical Activity
(A) Action potential firing in an a cell in an intact
mouse islet at 1 mM glucose before, during, and
after addition of 10 nM GLP-1 (horizontal line).
(B) Examples of action potentials taken under
control conditions (i), during the transient repolar-
ization (ii), and at ‘‘steady state’’ at the end of the
GLP-1 application (iii).
(C) As in (A) but testing the effects of 100 nM
u-conotoxin on an isolated a cell.
(D) Examples of action potentials recorded before
(i) and after addition of u-conotoxin (ii).
(E) As in (A), but 5 mM adrenaline was applied.
(F) Examples of action potentials under control
conditions (i) and broad action potentials seen in
the presence of adrenaline (ii).
(G) As in (A) but testing the effects of 100 nM
somatostatin.
(H) Action potential recorded under control condi-
tions (i) and when electrical activity had resumed in
the continued presence of somatostatin (ii).
In (A), (C), (E), and (F), the dotted horizontal lines
indicate zero mV (top) and –50 mV (lower).
Figure 7. GLP-1 Blocks N-Type Ca2+ Channels and Inhibits
Exocytosis
(A) Whole-cell Ca2+ currents evoked by membrane depolarization from 70 to
0 mV under control conditions (Ctrl; 1 mM glucose), 5 min after addition of
GLP-1 (10 nM), and 5 min after addition of 100 nM u-conotoxin in the
continued presence of GLP-1 (GLP-1 and u-con; gray).
(B) Current (I)-voltage (V) relationship recorded using the perforated patch
whole-cell configuration under control conditions (,; n = 10), 5 min after addi-
tion of 10 nM GLP-1 (d; n = 10), and 5 min after addition of u-conotoxin
(100 nM, u-con) in the continued presence of GLP-1 (:; n = 6). *p < 0.05 for
effects of GLP-1 versus control.
(C and D) As in (A) and (B) but recorded under control conditions (Ctrl, black),
6 min after the addition of 10 mM 8-Br-Rp-cAMPS (Rp; dark gray) and 4 min
after addition of 100 nM GLP-1 in the continued presence of 8-Br-Rp-cAMPS
(Rp and GLP-1; light gray) in a cells.
(E) Changes in membrane capacitance (DCm) elicited by ten voltage-clamp
depolarizations from 70 to 0 mV under control conditions (1 mM glucose;,),
after the addition of 10 mM 8-Br-Rp-cAMPS (:) and in the simultaneous pres-
ence of 10 nM GLP-1 8-Br-Rp-cAMPS (d).
(F) Histogram of the mean increase in membrane capacitance elicited by the
entire train (Total) and increase evoked by the two first depolarizations
(RRP). n = 6; *p < 0.05, **p < 0.01.
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Inhibition of Glucagon Secretion by GLP-119 mV (Figure 6G). Both these effects promptly reversed upon
removal of the hormone from the perfusion medium.
The effects of GLP-1 were also analyzed in isolated a cells
(Table S1). GLP-1 reduced the peak of the action potentials by
20 mV but did not affect interspike voltage and the frequency.
These effects of GLP-1 were blocked by exendin (9-39).
GLP-1 Inhibits N Type Ca2+ Channels
The findings that u-conotoxin mimics the inhibitory effect of
GLP-1 and that the incretin exerts no further inhibitory effect in
the presence of the N-type Ca2+ channel blocker (Figure 5D)
suggest that GLP-1 inhibits glucagon secretion by modulation
of N-type Ca2+ channel activity. We investigated this possibility
by perforated patch whole-cell measurements of a cell Ca2+
currents. GLP-1 inhibited the Ca2+-current by 20% during
depolarizations to 10 and 0 mV (Figures 7A and 7B). When
applied to a cells already exposed to GLP-1, the N-type Ca2+
channel blocker produced no additional inhibition; u-conotoxin
when applied in the absence of GLP-1 reduced the Ca2+ current
by 17% ± 7% (n = 5; p < 0.05; Figure S5B). The effects of GLP-1
on the N-type Ca2+ channels are mediated by activation of PKA;
no inhibition was observed in a cells exposed to the PKA inhibitor
8-Br-Rp-cAMPS (Figures 7C and 7D). GLP-1 was without effect
on non-N-type Ca2+ currents as well as voltage-gated Na+
currents (data not shown).
Inhibition of N-type Ca2+ channels with u-conotoxin inhibits
a cell exocytosis (Macdonald et al., 2007). Given that GLP-1
mimics the effect of the N-type Ca2+ channel blocker on the
Ca2+ current, it should exert anu-conotoxin-like effect on exocy-
tosis. We have previously observed that GLP-1 when applied to
a cells exposed to 5 mM glucose stimulates exocytosis (Ma et al.,
2005). However, it is possible that the effects of glucose and
GLP-1 in a cells interact. We therefore re-examined the effect
of GLP-1 at 1 mM glucose. Exocytosis was evoked by a train
of ten 500 ms depolarizations from 70 to 0 mV (Figure 7E). In
a series of six experiments, exocytosis was reduced by 60%
(Figure 7F). It was confirmed that exocytosis was stimulated by
GLP-1 in the presence of 5 mM glucose (285% ± 125% at
10 mV, n = 7 paired experiments, p < 0.015; data not shown).
DISCUSSION
The ability of GLP-1 to both stimulate insulin secretion and inhibit
glucagon secretion makes it unique and valuable as a diabetes
therapeutic hormone. GLP-1 inhibits glucagon release without
concomitant stimulation of insulin or somatostatin release
and was unaffected by inclusion of the SSTR2 antagonist
CYN154806 (Figure 1 and Figure S1). The finding that GLP-1
affects action potential firing in isolated a cells also indicates
that GLP-1 acts directly on the a cell and not via paracrine mech-
anisms. It is therefore intriguing that the expression of Glp1r
(the GLP-1 receptor gene) was very low in a cells (<0.2% of
that in b cells and only 1%–2% of that of Gipr, Adrb1, and
Adrb2 in a cells; Figures 1F and 1G). This low level of expression
is in agreement with previous PCR and immunocytochemical
data (Moens et al., 2002; Tornehave et al., 2008). We can discard
the possibility that GLP-1 exerts its effect on glucagon release by
activation of novel GLP-1 receptor undetected by the PCR
primers and the antibody. This is suggested by the finding thatCthe inhibitory effect of GLP-1 was abolished by the GLP-1
receptor antagonist exendin (9-39). As will be discussed below,
the low a cell GLP-1 receptor density has important functional
implications and is, in fact, a prerequisite for its inhibitory action.
Cyclic AMP Both Inhibits and Stimulates Glucagon
Secretion: Roles of PKA and Epac2
It is possible that the intracellular cAMP concentration may be
approximately proportional to the number of Gs-coupled mem-
brane receptors activated. We investigated the consequences
this might have on glucagon release by exposing pancreatic
islets to increasing concentrations of the adenylate cyclase
activator forskolin (0.1 nM–10 mM). We found that high concen-
trations of forskolin (R1 mM) mimicked the stimulatory effect ofell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc. 549
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trations (1–10 nM) mimicked the inhibitory effect of GLP-1.
Thus, GIP and adrenaline are 100- to 1000-fold more potent
than GLP-1 (in agreement with the PCR data) at stimulating
cAMP production when their effects are expressed as ‘‘forskolin
equivalents.’’
It is pertinent that the inhibitory effect of a low (3 nM) concentra-
tion of forskolin is prevented by pharmacological inhibition of
PKA, whereas the stimulatory effects of 10 mM forskolin are resis-
tant to this treatment (Figure 3B). From this we conclude that the
effects of low intracellular concentrations of cAMP are mediated
by activation of PKA. As the effects of the higher concentrations
of cAMP or forskolin are resistant to pharmacological inhibition of
PKA, it seems likely that they are mediated by activation of the
low-affinity cAMP-sensor Epac2 (Shibasaki et al., 2007). Indeed,
intracellular application of the Epac2 activator 8-CPT-2Me-
cAMP mimics the effect of high intracellular cAMP concentration
on exocytosis (Figures 4E and 4F and Figure S4).
Adrenaline Exerts Both Inhibitory and Stimulatory
Effects on Glucagon Secretion, Depending
on Receptor Occupancy
The observation that adrenaline, like forskolin, exerts concentra-
tion-dependent inhibitory or stimulatory effects on glucagon
secretion (Figures 2A and 2D) has important physiological and
pathophysiological implications. Stimulation of glucagon secre-
tion was only observed at concentrations >1 mM, and concentra-
tions of 5 nM were as inhibitory as GLP-1 (Figure 2D). For
comparison, the plasma concentrations of adrenaline in mice
range from a basal 1–30 nM during severe stress (Grouzmann
et al., 2003). Thus, circulating adrenaline is likely to inhibit rather
than stimulate glucagon release. As stimulation only occurs at
concentrations 1000-fold higher, it is possible that local release
from intra-islet (nor-) adrenergic nerve endings mediates the
stimulatory effects on glucagon secretion. The ability of electric
stimulation of the splanchnic nerve to increase pancreatic
glucagon secretion supports this scenario (Holst et al., 1986).
Low plasma concentrations of adrenaline may have similar
inhibitory effects on glucagon secretion to GLP-1 due to a similar
number of receptors being activated. Adrenaline binds to b1 and
b2 adrenergic receptors with Ki values of 106 M (Bylund et al.,
2009). This means that at concentrations of 1–10 nM of adrena-
line, only 0.1%–1% of the receptors will be activated. As b-adre-
noreceptors are expressed at levels 100-fold higher than Glp1r,
a saturating concentration of GLP-1 (10–100 nM; Kd = 0.5 nM;
Bylund et al., 2009) would activate a similar number of receptors.
Diabetes has been reported to be associated with reduced
expression of b-adrenergic receptors in the heart (Bidasee
et al., 2008), endothelium (Bucci et al., 2004), liver, and kidney
(Xu et al., 2008). If the expression of b-receptors is also reduced
in the pancreatic a cells, it is possible that the inhibitory effect of
adrenaline on glucagon secretion would prevail. This would
explain why impaired counterregulation is often seen in diabetic
patients (Cryer, 2002).
Model
Based on these observations, we propose the following model
for the regulation of glucagon secretion (Figure S6). The a cell is
electrically active during hypoglycemia. Voltage-gated N- and550 Cell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc.L-type Ca2+ channels open during the firing of action potentials.
Ca2+ entry via the N-type Ca2+ channels triggers exocytosis of
glucagon-containing secretory vesicles. This accounts for the
high rate of glucagon secretion during hypoglycemia (Fig-
ure S6A). Although the N-type Ca2+ channels only account
for <20% of the whole-cell Ca2+ current (Figure S5C), application
of u-conotoxin inhibited glucagon secretion while only having
a marginal effect on [Ca2+]i and action potential firing. Inhibition
of the L-type Ca2+ channels (which account for 70% of the
current [Macdonald et al., 2007]) was almost without inhibitory
effect (Figures 5D–5F). The inhibitory effect of u-conotoxin is
as strong as that produced by the broad-spectrum Ca2+ channel
blocker Co2+ (Gromada et al., 2004). This supports the hypoth-
esis that the glucagon granules are tightly associated with
N-type Ca2+ channels. Thus, the conduit of Ca2+ entry is more
important than overall [Ca2+]i in regulating exocytosis. This may
explain why there is such a weak apparent correlation between
[Ca2+]i and glucagon release (Figure 5).
Postprandial release of GLP-1 inhibits glucagon secretion.
GLP-1 binds to the low number of GLP-1Rs and causes a small
increase in intracellular cAMP concentration that is just sufficient
to activate PKA. PKA-dependent phosphorylation of N-type Ca2+
channels leads to strong inhibition of their activity and a reduction
in exocytosis (Figure S6B). Inhibition of N-type Ca2+ channels by
PKA has not been reported previously, but it is pertinent that this
effect is not detectable in the presence of 8-Br-Rp-cAMPS
(Figures 7C and 7D). GLP-1 (like u-conotoxin) has only a weak
effect on a cell electrical activity. The fact that the effect on a cells
in intact islets is weaker than that seen in isolated a cells is prob-
ably a consequence of N-type Ca2+ current (20 pA) comprising
a smaller fraction (5%) of the total inward current inacells within
intact islets (400 pA), whereas its relative contribution is more
important (30%) in isolated a cells (40 pA of 130 pA).
At first glance, the transient repolarization produced by GLP-1
in a cells resembles that produced by somatostatin (Figures 6A
and 6D). However, more detailed inspection counters the argu-
ment that somatostatin mediates the inhibition of glucagon
secretion. First, the repolarizing effect of GLP-1 is only transient
and followed within a few minutes by a slight depolarization and
reduction in action potential height. In contrast, somatostatin
produced a sustained hyperpolarization and increased action
potential height. Second, GLP-1 does not stimulate somato-
statin secretion measured over 1 hr incubations (Figure S1B).
This is consistent with the theory that any stimulation of the
d cell by GLP-1 is transient. Third, the inhibitory effect of
GLP-1 is (as already discussed above) maintained in the pres-
ence of SSTR2 antagonists.
GLP-1 and glucose both inhibit glucagon secretion by a mech-
anism involving reduced N-type Ca2+ channel activity. We have
proposed that glucose acts by closing KATP channels. The
KATP channel activator diazoxide, which reverses the inhibitory
action of glucose, does not antagonize the inhibitory effects of
GLP-1 (Figures S7A and S7B). This suggests that GLP-1 does
not act by closure of the KATP channels. This conclusion is sup-
ported by the absence of any sustained effect of GLP-1 on the
interspike membrane potential (Figure 6A). Thus, GLP-1 and
glucose inhibit glucagon secretion by different mechanisms.
GLP-1 inhibits glucagon secretion by PKA-dependent modu-
lation of the N-type Ca2+ channels. Glucose, however, influences
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potential resulting from closure of the KATP channels. This is sup-
ported by the finding that GLP-1 enhances the inhibitory effect
of glucose whereas glucose exerts little additional inhibitory
action when glucagon secretion is already suppressed by
GLP-1 (Figure 1C).
Adrenaline activates 100- to 1000-fold more Gs-coupled
receptors than GLP-1 and thereby produces a larger increase
in intracellular cAMP concentration (Figure S7C). This leads to
activation of PKA-RI and, in common with GLP-1, inhibits the
N-type Ca2+ channels. However, the large increase in cAMP also
activates the low-affinity cAMP sensor Epac2. This increases
Ca2+ influx via the L-type Ca2+ channels (Figures 4C and 4D),
in agreement with previous results in b cells (Shibasaki et al.,
2004). This expands the active zone of [Ca2+]i capable of trig-
gering exocytosis. Granules further away from the channels
can now also undergo exocytosis. Indeed, the Ca2+ sensitivity
of exocytosis increases by a factor of >3.5 (determined from
the slopes in Figure S4C).
The switch from N- to L-type Ca2+ channels correlates with an
10 mV shift in the voltage dependence of exocytosis toward
negative membrane potentials. This allows significant exocy-
tosis at voltages as negative as 20 mV (Figures 3D and 3E).
This is significant because adrenaline depolarized the a cell by
10 mV and reduces the action potential peak voltage to
–20 mV. If the voltage dependence of exocytosis had not
changed, action potential firing in the presence of adrenaline
would not produce much stimulation of glucagon release (Fig-
ures 3 and 6). These effects of high intracellular cAMP (that affect
the magnitude of the Ca2+ current, the duration of the action
potentials, and release probability of the secretory granules)
account for the stimulation of glucagon release by adrenaline.
It has been suggested that adrenaline depolarizes the a cell
through a store-operated mechanism (Liu et al., 2004). More
work is required to establish precisely how adrenaline depolar-
izes the a cell and extends the action potential duration.
Exocytosis triggered by intracellular application of the Epac2-
selective agonist 8CPT-2Me-cAMP is partially resistant to the
L-type Ca2+ channel antagonist isradipine (Figure 4B), whereas
exocytosis elicited by standard cAMP in the electrode solution
is almost entirely dependent on L-type Ca2+ channels (Figure S4).
This difference may be due to the inhibition of N-type Ca2+ chan-
nels by PKA, which is activated by cAMP. However, 8CPT-2Me-
cAMP does not activate PKA, so the isradipine-resistant compo-
nent of exocytosis may be caused by Ca2+ influx via N-type Ca2+
channels. In addition to the activation of Epac2 and PKA-RI,
adrenaline also activates PKA-RII, which requires higher cAMP
levels than PKA-RI (Di Benedetto et al., 2008) and has a more
cytoplasmic localization. We speculate that this promotes mobi-
lization of secretory granules to release sites. This would account
for the PKA-sensitive component of adrenaline-induced glu-
cagon secretion that persists in the Epac2/ islets (Figure 4F).
Our estimates of the relative contribution of the PKA-depen-
dent and -independent (Epac2-mediated) mechanisms to glu-
cagon secretion are rather variable (compare Figures 1A, 1B,
and 4). There are at least two explanations for this. First, the
effects of b-adrenergic stimulation on intracellular cAMP content
may vary leading to a variable activation of Epac2. This might
account for the different magnitude of the 8-Br-Rp-cAMPS-Cresistant component seen in NMRI (Figure 1) and C57Bl6J
mice (Figure 4). Second, there is a crosstalk between the PKA-
and Epac2-mediated effects on exocytosis. Activation of PKA
will, by affecting the rate of granule mobilization/priming
(Gromada et al., 1997), influence the number of granules for
Epac2 to act on. After inhibition of PKA, the size of the readily
releasable pool is reduced, and this limits the stimulation pos-
sible by Epac2 activation.
Conclusions
We show here that GLP-1 inhibits glucagon release by a direct
effect on the pancreatic a cell that is mediated by GLP-1 recep-
tors. The action in part involves the same intracellular signaling
pathways as those utilized by adrenaline to stimulate glucagon
secretion. In general, there is a good agreement between the
effects we now report in mouse islets with preliminary observa-
tions made in human islets.
We postulate that there is a direct correlation between the
number of receptors and the capacity of the agonists to elevate
intracellular cAMP. The divergent effects of adrenaline and
GLP-1 can thus be explained by the much lower a cell expres-
sion of the GLP-1 receptors than of the b-adrenoreceptors.
Although the actions of both compounds are mediated by eleva-
tion of cytoplasmic cAMP, adrenaline leads to much larger
increases and thereby activates the low-affinity cAMP sensor
Epac2 in addition to PKA. These results also illustrate that phys-
iologically highly significant effects can be exerted by membrane
receptors expressed at such low levels that they almost escape
detection by immunocytochemistry and quantitative PCR.
EXPERIMENTAL PROCEDURES
Islets and Preparation of Cells
Islets from NMRI mice were isolated by collagenase digestion and cultured in
RPMI-1640 media (5 mM glucose) at 37C and 5% CO2 for 224 hr prior to
secretion or intracellular Ca2+ assays. For single cell studies, islets were
dispersed in a Ca2+-free buffer and plated in 35 mm plastic dishes. Epac2-defi-
cient mice were generated as previously described (Shibasaki et al., 2007). For
the latter studies, normal age-matched C57Bl6J mice were used as controls
(wild-type).
Hormone Release
Briefly, batches of ten freshly isolated islets were preincubated in 1 ml of
Krebs-Ringer buffer (KRB) supplemented with 1 mM glucose for 30 min fol-
lowed by a 1 hr incubation in 1 ml of test KRB supplemented as indicated.
Hormone contents were determined as described elsewhere (Heding, 1966;
Panagiotidis et al., 1992; Tronier and Larsen, 1982). When extracellular KCl
was increased, NaCl was correspondingly reduced to maintain iso-osmolarity.
GLP-1, GIP, and exendin (9-39) were obtained from Bachem. KRB containing
adrenaline was supplemented with ascorbic acid (10 mM) to prevent oxidation
of the compound. BSA at a concentration of 0.1% was included in all these
experiments.
The experiments were conducted over 6 years, in different laboratories and
in different countries. To facilitate comparison between the different experi-
mental series, glucagon secretion has been normalized to that measured
under control (0 or 1 mM glucose) conditions. The latter values are given for
the individual experimental series in the figure legends.
Measurements of Islet cAMP Content
Freshly isolated islets were preincubated for 2 hr at 37C in RPMI containing no
glucose and supplemented with 0.05% BSA. The supernatant was discarded,
and the islets were incubated at 37C for 30 min in 1 ml of KRB-BSA medium
containing 1 mM glucose and 100 mM isobutyl methylxanthine (IBMX),ell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc. 551
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natant was removed immediately after incubation and frozen for glucagon
assay. cAMP was extracted by adding 400 ml of ice-cold sodium acetate buffer
(50 mM, pH 6.2) to the islets. Pellet samples were boiled for 10 min and soni-
cated on ice before being stored at 80C. cAMP levels were determined by
RIA (Amersham Pharmacia Biotech, Braunschweig, Germany).
Flow Cytometry of Islet Cells
Flow cytometry of isolated islet cells from transgenic mice expressing the fluo-
rescent protein Venus under the proglucagon promoter was performed using
a Dakocytomation MoFlo cell sorter, with excitation set at 488 nm and emis-
sion monitored at 530 and 580 nm (Reimann et al., 2008). Cells were sorted
into 1 ml of RNAlater (Ambion). Based on the mRNA content, the Venus-posi-
tive fraction consisted exclusively of a cells (99.98% based on glucagon,
insulin, and somatostatin mRNA transcripts). Corresponding Venus-negative
cells were sorted in parallel into a separate tube (99.97% b cells based on
mRNA content).
RNA Extraction and Quantitative RT-PCR
Total RNA was purified from the purified cell fractions using RNeasy Mini kit
(QIAGEN) followed by DNase digestion (RQ1 DNase, Promega) and reverse
transcription (SuperScript III, Invitrogen), according to the manufacturers’
instructions. The resulting cDNA was subjected to 40 cycles of quantitative
real-time PCR (RotorGene 2000, Corbett Research) in 10 ml reactions contain-
ing 13 JumpStart PCR Master Mix (Sigma) and 0.2 mM primers (Gene ID;
forward primer; reverse primer: Glp1r; CCAGGTTCCTTCGTGAATGT; GCAGG
CTGGAGTTGTCCTTA: Gipr; AGACCAGGCCCCTACCC; TGTAATTGGCTCC
CACACAA: Adrb1; GATCTGGTCATGGGATTGCT; CACACAGGGTCTCAATG
CTG: Adrb2; CGACTACAAACCGTCACCAA; GTCCAGAACTCGCACCAGA).
Data were normalized to the expression levels of ribosomal protein S29
(Rps29) and hypoxanthine guanine phosphoribosyl transferase 1 (Hprt) in
each sample. Data have been normalized to expression of Glp1r in b cells
(assigned as 100%).
Immunocytochemistry
GLP-1R immunoreactivity in mouse pancreases was detected using methods
similar to those reported elsewhere (Braun et al., 2009) using rabbit anti-GLP-
1R (LS-A-1205 and LS-A-1206, Lifespan, 1:100 and 1:750, respectively) anti-
bodies.
PKA regulatory subunit type 1 (PKA-RI) and type 2 (PKA-RII) immunoreac-
tivity was detected in mouse a cells cultured overnight on glass coverslips,
fixed with 4% paraformaldehyde in PBS for 1 hr, and permeabilized with 5%
Triton X-100 overnight. The primary antibodies were mouse monoclonal
anti-PKA RI (BD Biosciences, NJ; 1:50), goat anti-PKA RII (Upstate, Temecula,
CA; 1:50), and guinea pig anti-glucagon (Jackson Immunoresearch Laborato-
ries Inc, West Grove, PA; 1:500). Unspecific binding was blocked with 5%
normal donkey serum (Jackson Immunoresearch Laboratories Inc, West
Grove, PA). The secondary antibodies were anti-goat Cy5 (1:50) and anti-
mouse Cy3 (1:50; both from Jackson Immunoresearch Laboratories Inc).
Intracellular Ca2+ Measurements
Intact islets were loaded with fluo-4-AM (2.5 mM; from Invitrogen) in RPMI-
1640 media (5 mM glucose) for >1 hr at room temperature. Islets were fixed
with a wide-bore holding pipette and were continuously superfused and
temperature controlled (37C). The perfusion buffer contained (in mM)
139 NaCl, 4.7 KCl, 2 NaHCO3, 0.5 NaH2PO4, 0.5 MgSO4, 5 HEPES (pH 7.4
with NaOH), 2.6 CaCl2, 1 glucose. GLP-1 (7-36) amide was obtained from
Bachem. Laser scanning confocal microscopy was performed using an
LSM 510 meta system (Zeiss). Excitation was with a 488 nm argon laser,
and emitted fluorescence was collected through 500–550 nm band-pass
filter. Increases in intracellular Ca2+ are displayed as upward deflections.
Images were acquired at 1.5–2.5 s intervals. Prior to experimental recordings,
islets were perfused for 10 min with the appropriate control solution. The
recordings were replayed off-line, and regions of interest (ROI) were selected
and analyzed using the Zeiss LSM 510 software. All [Ca2+]i data have been
normalized to the responses in control experiments of the same duration in
1 mM glucose alone to compensate for any time-dependent decrease in
fluo-4 fluorescence.552 Cell Metabolism 11, 543–553, June 9, 2010 ª2010 Elsevier Inc.Capacitance Measurements and Whole-Cell Recordings of
Membrane Currents and Voltages
Whole-cell currents and exocytosis were recorded using an EPC-9 patch-
clamp amplifier (HEKA Electronics, http://www.heka.com/) and Pulse soft-
ware (version 8.50). Exocytosis was monitored as changes in a cell capaci-
tance using the software-based lock-in function of the Pulse software. Single
a cells were identified by their small size and Na+ current inactivation proper-
ties (Barg et al., 2000). The validity of this method was confirmed by immunos-
taining as previously described (Braun et al., 2008). The extracellular medium
contained (in mM) 118 NaCl, 20 TEA-Cl (tetraethylammonium chloride),
5.6 KCl, 2.6 CaCl2, 1.2 MgCl2, 5 HEPES (pH 7.4 with NaOH), and glucose as
indicated. Except for Figures 4C and 4D and Figure S5, in which the standard
whole-cell configuration was used, the electrophysiological measurements
were conducted using the perforated patch technique, and the pipette solution
contained (in mM) 76 Cs2SO4, 10 NaCl, 10 KCl, 1 MgCl2 and 5 HEPES (pH 7.35
with CsOH). Perforation was produced by addition of amphotericin B at a final
concentration of 60 mg/ml amphotericin as previously described (Ammala
et al., 1993). The standard whole-cell measurements were conducted using
a pipette solution (dialyzing the cell interior) which consisted of (in mM)
125 CsOH, 125 glutamate, 10 CsCl, 10 NaCl, 1 MgCl2, 5 HEPES (pH 7.15
with KOH), 3 Mg-ATP, and 25 mM EGTA (measured resting free Ca2+, 0.2 mM).
Pulses were applied at low frequency (<0.05 Hz) to allow the exocytotic
capacity to recover fully between the pulses.
Membrane potentials were recorded from a cells in intact islets essentially
as described previously (Gopel et al., 1999). The data were analyzed using
Clampfit 9 (Molecular Devices, Sunnyvale, CA). Interspike potentials were
derived from Gaussian fit which was applied to all-point histograms of the
potential recording. Action potential peaks were detected using the Event
Detection/Threshold Search program of Clampfit 9 (threshold level set to
20 mV). Action potential peak amplitudes were determined from a Gaussian
fit to the distribution of all the events.
Statistical Analysis
Data are presented as means and standard errors. Significance was examined
by either the paired or unpaired t test and, when appropriate, by multiple-
comparisons analysis of variance (ANOVA) and posttest.
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